The Seattle Post Myocardial Infarction Model (SPIM): Prediction of mortality after acute myocardial infarction with left ventricular dysfunction

European Heart Journal: Acute Cardiovascular Care

Volumn 3, Issue 1, 2014, Pages 46-55

  Ketchum, Eric S ^a   Dickstein, Kenneth ^b   Kjekshus, John ^c   Pitt, Bertram ^d   Wong, Meagan F ^a   Linker, David T ^a   Levy, Wayne C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Myocardial infarction; risk model; survival

Indexed keywords

AGED; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; NORWAY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL RATE; TIME; TRENDS; UNITED STATES;

AGED; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; NORWAY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84907061639     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872613502283     Document Type: Article

References (47)

1. Krumholz HM, Wang Y, Chen J, et al. Reduction in acute myocardial infarction mortality in the United States: Riskstandardized mortality rates from 1995–2006. JAMA 2009; 302: 767–773.
2. Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010; 362: 2155–2165.
3. Puymirat E, Simon T, Steg PG, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA 2012; 308: 998–1006.
4. Jernberg T, Johanson P, Held C, et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011; 305: 1677–1684.
5. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 2007; 356: 2388–2398.
6. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345–2353.
7. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284: 835–842.
8. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102: 2031–2037.
9. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000; 101: 2557–2567.
10. McManus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 2011; 124: 40–47.
11. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics – 2012 update: A report From the American Heart Association. Circulation 2012; 125: e2–e220.
12. Dickstein K, Gleim GW, Snapinn S, et al. The impact of morbid events on survival following hospitalization for complicated myocardial infarction. Eur J Heart Fail 2006; 8: 74–80.
13. Jacobs DR, Jr, Kroenke C, Crow R, et al. PREDICT: A simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: The Minnesota Heart Survey. Circulation 1999; 100: 599–607.
14. Brilakis ES, Wright RS, Kopecky SL, et al. Association of the PURSUIT risk score with predischarge ejection fraction, angiographic severity of coronary artery disease, and mortality in a nonselected, community-based population with non- ST-elevation acute myocardial infarction. Am Heart J 2003; 146: 811–818.
15. Truong QA, Cannon CP, Zakai NA, et al. Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. Am Heart J 2009; 157: 673–679.
16. Garg S, Sarno G, Garcia-Garcia HM, et al. A new tool for the risk stratification of patients with complex coronary artery disease: The Clinical SYNTAX Score. Circ Cardiovasc Interv 2010; 3: 317–326.
17. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004; 291: 2727–2733.
18. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321.
19. Pitt B, Williams G, Remme W, et al. The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15: 79–87.
20. Dickstein K and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–760.
21. Dickstein K and Kjekshus J. Comparison of baseline data, initial course, and management: Losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 2001; 87: 766–771, A7.
22. Hanley JA and McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29–36.
23. Lemeshow S and Hosmer DW, Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982; 115: 92–106.
24. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356–362.
25. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.
26. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010; 304: 1350–1357.
27. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298: 765–775.
28. Pepine CJ, Kowey PR, Kupfer S, et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol 2006; 47: 547–551.
29. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle heart failure model: Prediction of survival in heart failure. Circulation 2006; 113: 1424–1433.
30. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397–1402.
31. Giugliano RP, Llevadot J, Wilcox RG, et al. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J 2001; 22: 1702–1715.
32. Alberts MJ, Bhatt DL, Mas JL, et al. Three-year followup and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J 2009; 30: 2318–2326.
33. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197–1206.
34. Cohen MG, Pacchiana CM, Corbalan R, et al. Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Am Heart J 2001; 141: 391–401.
35. Gibson CM, Pinto DS, Murphy SA, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003; 42: 1535–1543.
36. Kumler T, Gislason GH, Kober L, et al. Renal function at the time of a myocardial infarction maintains prognostic value for more than 10 years. BMC Cardiovasc Disord 2011; 11: 37.
37. Giraldez RR, Sabatine MS, Morrow DA, et al. Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction. Am Heart J 2009; 157: 517–524.
38. Anker SD, Voors A, Okonko D, et al. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: Data from the OPTIMAAL trial. Eur Heart J 2009; 30: 1331–1339.
39. Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005; 111: 2454–2460.
40. Bangalore S, Messerli FH, Ou FS, et al. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: Results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J 2010; 31: 552–560.
41. Antoni ML, Boden H, Delgado V, et al. Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J 2012; 33: 96–102.
42. Wiviott SD, Morrow DA, Frederick PD, et al. Application of the thrombolysis in myocardial infarction risk index in non- ST-segment elevation myocardial infarction: Evaluation of patients in the National Registry of Myocardial Infarction. J Am Coll Cardiol 2006; 47: 1553–1558.
43. Yan AT, Yan RT, Cantor WJ, et al. Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: Insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Eur Heart J 2011; 32: 1994–2002.
44. Van Domburg RT, Sonnenschein K, Nieuwlaat R, et al. Sustained benefit 20 years after reperfusion therapy in acute myocardial infarction. J Am Coll Cardiol 2005; 46: 15–20.
45. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 57: 215–367.
46. Bagnall AJ, Yan AT, Yan RT, et al. Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: Exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. Circ Cardiovasc Qual Outcomes 2010; 3: 530–537.
47. Yan AT, Yan RT, Huynh T, et al. Understanding physicians' risk stratification of acute coronary syndromes: Insights from the Canadian ACS 2 Registry. Arch Intern Med 2009; 169: 372–338.